Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer

Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer is a phase 2, randomised interventional study registered as NCT06121505 by Sichuan University, with a registry enrolment figure of 114 participants, started 2024-03-01 and due to reach its primary completion in 2027-02-28. Interventions recorded: low-dose radiation therapy and stereotactic body radiation therapy; chemotherapy; Sintilimab. Conditions listed: Lung Squamous Cell Carcinoma. Primary outcome: objective response rate (ORR). Lung eligibility wording from the registry: "Histologically or cytologically confirmed squamous cell lung cancer, imaging confirmed locally advanced or metastatic disease (unresectable or not eligible for definitive chemoradiotherapy, stage IIIB-IV);". Sites: China. No results are recorded here; the registry entry is the source.